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Here, we report two novel GUCA1A (the gene for guanylate cyclase activating protein 1) mutations identified in unrelated
Spanish families affected by autosomal dominant retinal degeneration (adRD) with cone and rod involvement. All patients
from a three-generation adRD pedigree underwent detailed ophthalmic evaluation. Total genome scan using single-nucleotide
polymorphisms and then the linkage analysis were undertaken on the pedigree. Haplotype analysis revealed a 55.37Mb genomic
interval cosegregating with the disease phenotype on chromosome 6p21.31-q15. Mutation screening of positional candidate genes
found a heterozygous transition c.250C>T in exon 4 of GUCA1A, corresponding to a novel mutation p.L84F. A second missense
mutation, c.320T>C (p.I107T), was detected by screening of the gene in a Spanish patients cohort. Using bioinformatics approach,
we predicted that either haploinsufficiency or dominant-negative effect accompanied by creation of a novel function for the mutant
protein is a possible mechanism of the disease due to c.250C>T and c.320T>C. Although additional functional studies are required,
our data in relation to the c.250C>T mutation open the possibility that transacting factors binding to de novo created recognition
site resulting in formation of aberrant splicing variant is a diseasemodel whichmay bemore widespread than previously recognized
as a mechanism causing inherited RD.
1. Introduction
Autosomal dominant cone and cone-rod dystrophies
(adCODs and adCORDs, resp.) are hereditary retinal disor-
ders characterized by visual loss, abnormalities of color
vision, visual field loss, and a variable degree of nystagmus
and photophobia. CORDs are characterized by progressive
loss of cone photoreceptor function followed by progressive
loss of rod photoreceptor function and are often accompanied
by retinal degeneration. In contrast, in inherited progressive
CODs, only cone function is impaired, and retinal degener-
ation is often restricted to the central retina [1, 2].
COD and CORD are genetically heterogeneous disorders
with phenotype caused by mutations in currently ten genes,
including AIPL1, CRX, GUCA1A, GUCY2D, PITPNM3,
PROM1, PRPH2/RDS, RIMS1, SEMA4A, and UNC119
(https://sph.uth.edu/retnet/). Four loci (CORD4, RCD1,
CORD12, and CORD17) with still unidentified genes have
been also linked to adCOD and adCORD (https://sph.uth
.edu/retnet/).
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Table 1: Mutation prediction for known and novel GUCA1A variations.
Mutation Domain PolyPhen-2
a PSIPREDb Dystrophy Reference
Prediction Human var score Protein secondary structure change
P50L Benign 0.132 Yes Cone, rod-cone [3]
L84F PRD 0.999 No Cone, cone-rod, macular Novel
E89K EF3 PSD 0.681 Yes Cone [4]
Y99C EF3 PRD 1.000 Yes Cone, cone-rod, macular [5, 6]
D100E EF3 PRD 0.999 Yes Cone [4]
N104K EF3 PRD 0.998 Yes Cone [7]
I107T EF3 PRD 1.000 Yes Cone, cone-rod, macular Novel
T114I EF3 Benign 0.009 Yes Atypical RP [8]
I143NT EF4 NP — Yes Cone [8]
L151F EF4 PRD 1.000 Yes Cone-rod [9, 10]
E155G EF4 PRD 1.000 Yes Cone [11]
G159V EF4 PRD 1.000 Yes Cone [4]
aPolyPhen-2 appraises mutations qualitatively as benign, possibly damaging (POS), or probably damaging (PRD) based on the model’s false positive rate. NP:
not performed.
bPSIPRED was used for secondary structure prediction, and the number of the resulting alterations is given in the table. For PSIPRED analysis, any predicted
changes in protein secondary structure were considered to be damaging mutations.
GUCA1A gene encodes one of three human guany-
late cyclase-activating proteins (GCAPs), GCAP1, which
is expressed in photoreceptors in the human retina, with
stronger GCAP1 immunoreactivity in cones than in rods [12].
A hallmark of the GCAP structure is high affinity Ca2+-
binding sites, called EF-hands, consisting of helix-loop-helix
secondary structure that is able to chelate Ca2+ ions [13]. Exci-
tation of the photoreceptor decreases the intracellular con-
centration of cyclic guanosine-3󸀠,5󸀠-monophosphate (cGMP)
and Ca2+. GCAP1 works as a Ca2+-sensor protein that
detects changes in Ca2+ concentration and stimulates mem-
brane bound retinal guanylate cyclases (RetGCs) in a Ca2+-
dependent manner. As a result, the cGMP level is restored
[14]. Since its identification, ten disease-causing mutations in
the GUCA1A gene have been reported to cause autosomal
dominant COD, CORD, and macular dystrophy (adMD) in
several unrelated families: p.P50L, p.E89K, p.Y99C, p.D100E,
p.N104K, p.T114I, p.I143NT, p.L151F, p.E155G, and p.G159V
[3–11] (Table 1).
In recent years, the importance of aberrant splicing as a
disease mechanism has changed from a situation in which
this possibility was considered to be relatively rare and only
relevant when one out of a few critical nucleotides in the
splice sites consensus sequences at the exon/intron borders
are changed to a situation where sequence variants in a gene
may potentially disrupt splicing. Thus, in addition to the
splice site sequences, other cis-regulatory elements which
act as splicing enhancers (exonic and intronic, ESEs, and
ISEs) or silencers (exonic and intronic, ESSs, and ISSs) and
direct the splicing machinery to use the correct splice sites
should be considered as important mutation spots [15]. The
interactions between silencers, enhancers, and their cognate
binding proteins play a critical role in the fidelity and
regulation of pre-mRNA splicing [16]. To our knowledge,
at least 10% of all mutations identified as causing human-
inherited disease are known to alter consensus 5󸀠- or 3󸀠-
splice sites, thereby inducing aberrant pre-mRNA splicing
[17]. Although the mechanistic consequences of mutations
on splice sites are fairly easy to interpret, evaluating precisely
how inherited disease-causingmutations influence the loss or
gain of ESE/ESS motifs remains challenging [18].
In this study, we report two Spanish families with an
autosomal dominant retinal degeneration in which two novel
GUCA1Amutations have been identified (Table 1). We inves-
tigated the relationship between the newly reported coding
sequence mutation (c.250C>T) and splicing regulation using
a set of bioinformatics techniques and predicted that ESE
loss and ESS gain might be responsible for retinal dystrophy.
Furthermore, we identified a range of retinal abnormalities
within a single pedigree caused by novel GCAP1 p.L84F vari-
ation which is consistent with the broader phenotype associ-
ated with p.Y99C and p.P50L GUCA1Amutations [5, 19].
2. Materials and Methods
2.1. Clinical Assessment and Sample Collection. This study
adhered to the tenets of the Declaration of Helsinki for
research involving human subjects. A three-generation Span-
ish family with an autosomal dominant retinal dystrophy was
ascertained (Figure 1(a)). Five affected and 9 unaffected indi-
viduals were recruited by the Hospital Fundacio´n Jimenez
Diaz, Madrid, Spain. After informed consent was obtained,
each patient was assessed through a funduscopy, an optical
coherence tomography (OCT) using macular cube scan
(512× 128 protocol), an electrooculogram (EOG), a full-field
electroretinogram (ERG), and a multifocal ERG (mfERG)
using standard electrophysiologic methods. Peripheral blood
was obtained by venipuncture, and genomic DNA was
extracted from lymphocytes according to standard protocols
[20].
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Figure 1: Continued.
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Figure 1: Identification of GUCA1A mutations in two Spanish pedigrees. (a), (d) Pedigrees of two unrelated families affected by adRD.
Individuals are identified by pedigree number. Squares indicate males, circles indicate females, slashed symbols indicate deceased, solid
symbols indicate affected individuals, open symbols indicate unaffected individuals, and arrow indicates the proband. In (a), pedigree of the
Family 141 is shown with haplotypes of STR markers spanning the linked interval on chromosome 6. Markers and their physical positions
(Mb) are indicated at the left of each row. Ten members indicated with asterisks were genotyped by SNPmarkers. C/C indicates two copies of
wild-type GUCA1A, and C/T indicates one copy of wild-type and one copy of mutant GUCA1A. In (d), T/C indicates one copy of wild-type
and one copy of mutant GUCA1A found in the proband III:2 in Family 387. (b), (e) Sequencing chromatograms showing the comparison
of DNA sequences of normal control (top) to the heterozygous C-to-T transition in exon 4 of GUCA1A (bottom) resulting in a leucine-to-
phenylalanine change (p.L84F; GenBank accession number JQ924784) at position 250 (b) and to the heterozygous T-to-C transition in exon
4 of GUCA1A (bottom) resulting in a isoleucine-to-threonine change (p.I107T; GenBank accession number JQ924785) at position 320 (e).
These mutations segregated with the disease phenotype and were not found in 200 normal controls. (c) Restriction fragment length analysis
confirmed the c.250C>T mutation showing that the transition from C to T results in the loss of restriction site of SmlI. Wild-type samples
produced two fragments of 276 bp and 241 bp, while the restriction target site (5󸀠-CTCAAG-3󸀠) in exon 4 of GUCA1A was destroyed by
the mutation. Analyzed individuals are identified by pedigree number, bp: base pair, and M: 100 bp DNA ladder. (f) Multiple amino acid
alignment of known vertebrate showing the evolutionary conservation of guanylate cyclase-activating proteins (only the region containing
EF2 and EF3 are shown). Amino acid residues are colored according to the similarity of their physicochemical properties. The conserved
12-amino-acids Ca2+-binding loop of EF3 is highlighted in grey. The two mutations occurring in high conserved amino acid region across
the species are localized next to EF2 (p.L84F) and within EF3 (p.I107T). (g) The region comprising the exonic splicing enhancer (ESE) and
silencer (ESS) motifs in the wild type (WT) exon 4 is compared to the corresponding region in the mutant (250T) exon 4 of GUCA1A. The
SF2/ASF binding ESE as well as two ESS recognition sites for hnRNP I (ESS1) and SRp20 (ESS2) are depicted. In the context of GUCA1A
exon 4, we have hypothesized that a binding ESE is disrupted in the case of 250T allele and thus the antagonizing function of SF2/ASF
is abolished. Instead, cryptic ESS sites for binding of hnRNP I and SRp20 exon inclusion suppressors are activated which results in exon
4 skipping. The strengthened motif TCTT binding hnRNP I is indicated in dark red. c.C250T substitution is depicted by underlying of the
nucleotide. (h) Cartoon representation of chickenGcap1 (PDB ID: 2R2I) with the Ca2+ binding EFhands rendered byVMD software. Residues
affected by mutation in the human orthologue are colored in red for Leu84 (corresponding to Leu83 in chicken Gcap1) and green for Ile107
(corresponding to Ile106 in chicken Gcap1.)
A cohort of 61 unrelated Spanish patients clinically
diagnosed with COD, CORD, or MD and family history
consistent with an autosomal dominant mode of inheritance
were additionally screened for mutations in GUCA1A gene.
In addition, 200 randomly selected DNA samples (400
chromosomes) from healthy control individuals obtained
from the European Collection of Cell Cultures (Human
Random Control DNA Panels, ECACC, Salisbury, UK) were
analyzed to assess the frequency of sequence changes in the
normal population.
2.2. Genotyping and Linkage Analysis. Genotyping of 10
members of the Spanish pedigree (Family 141, Figure 1(a))
was performed with 262,264 single nucleotide polymor-
phisms (SNPs) from the Affymetrix Gene Chip Mapping
250K Nsp Array (AROS Applied Biotechnologies, Aarhus,
Denmark). LOD scores were calculated for the markers by
multipoint linkage analysis using Genehunter program in the
easyLINKAGE Plus package v5.08 [21]. The call rate, defined
as the percentage of successful genotype calls among subjects,
was used as a measure of data quality. The results reported
in this study are based on 95% call rate. Uninformative SNPs
were removed from the data by Merlin [22]. We modeled the
disease as an autosomal dominant trait with 100%penetrance.
All regions with suggestive LOD scores (>1.5) were
additionally saturated with microsatellite (STR) markers
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designed according to the information obtained from
Marshfield, GDB Human Genome Database (http://research
.marshfieldclinic.org/) and Ensembl genome data resources
(http://www.ensembl.org/). Multiplex microsatellite geno-
typing of all available family members (Figure 1(a)) was
performed with 3–5 markers per reaction using QPCR mix
(ABgene, UK). Data collection and allele identification were
performed using GeneScan and GeneMapper v4.0 software
(Applied Biosystems Incorporated, Foster City, CA, USA).
2.3. Mutation Screening. Sequence analysis of the cod-
ing exons and intron-exon junctions of candidate genes
within the critical interval, IMPG1, ELOVL4, RDS, GUCA1A,
and RIMS1, was performed on ABI3730xl genetic analyser
(Applied Biosystems Incorporated, Foster City, CA, USA)
according to the manufacturer’s protocol. Novel nucleotide
sequences were compared to the published cDNA sequence
according to the human genome build 37 (hg19, 2009).
2.4. Restriction Enzyme Analysis. To confirm the presence
of c.250C>T variant, exon 4 of the human GUCA1A gene
was directly amplified from genomic DNA. A sample of
genomic DNA (100 ng) from patients and healthy individuals
was used in a 20𝜇L reaction mixture containing 0.5𝜇M
of forward (5󸀠 GTCTAGGAAGACAGATAGGTC 3󸀠) and
reverse (5󸀠 CAAGGAAGGGAAGGAACGTG 3󸀠) primers,
20𝜇M of each dNTP, 1× PCR buffer, and 1U of MyTaq DNA
polymerase (Bioline, London, UK). After an initial denatura-
tion of 95∘C for 5min, 30 cycles were performed at 95∘C for
30 s, 62∘C for 20 s, and 72∘C for 50 s, with a final extension step
of 72∘C for 5min. The PCR products (517 base pairs length)
were digested with SmlI according to the manufacturer’s
instructions (New England BioLabs, Beverly, MA, USA) and
separated by electrophoresis in a 3% agarose gel.
2.5. Mutation Prediction and In Silico Analyses of ESE and
ESS Motifs. Prediction of the possible effect of an amino
acid substitution on the structure and function of the
human protein was performed with the following software
tools. PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/)
generates a different scale of reported scores, where a
score of 0–0.2 is considered “benign,” 0.2–0.85 is “pos-
sibly damaging,” and 0.85–1.0 is “probably damaging”
[23]. PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/) is a sec-
ondary structure prediction method with a 80% accuracy
according to the (CASP Critical Assessment of Structure
Prediction techniques) contents [24], incorporating two
feed-forward neural networks which perform an analy-
sis on output obtained from PSI-BLAST (Position-Specific
Iterated-BLAST) [25]. Computer programs, Human Splicing
Finder 2.4.1 (http://umd.be/HSF/) [26] and ESEfinder 3.0
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) [27],
were used for prediction of ESE and ESS motifs present
in the wild-type or mutant GUCA1A exon 4 sequence.
Alternative Splicing Database (ASD), Splicing Rainbow
(http://www.ebi.ac.uk/) [28], and the ESRsearch web server
(http://esrsearch.tau.ac.il/) [29] were utilized for searching
of both ESE and ESS putative elements indicated by the
RESCUE-ESE [30], FAS-ESS [31], and (PESX Putative Exonic
Splicing Enhancers/Silencers) [32] servers.
2.6. Protein Structure Modeling. Chicken (Gallus gallus)
orthologue Gcap1 (PDB ID: 2R2I) was modeled using Visual
Molecular Dynamics (VMD) software (http://www.ks.uiuc
.edu/Research/vmd/) [33].
3. Results
3.1. Clinical Evaluation of Patients. Clinical evaluation
including fundus photography and electrophysiology was
performed in a three-generation Spanish pedigree with
autosomal dominant retinal degeneration with cone and rod
involvement (Family 141, Figure 1(a)). All affected individuals
complained of very early loss of central vision within the
first two decades (between age of 2 and 17 years), with
subsequent gradual deterioration of the color vision and
mild photophobia. There was no evidence of nystagmus.
Clinical characteristics of patients are summarized in
Tables 2 and 3. Funduscopy revealed a range of macular
phenotypes, from normal or mild changes to severe macular
atrophy (Figures 2(a)–2(j)). This variation was not related
to the age of the subjects. Despite the normal fundus
appearance in patient III:1, OCT scans showed that the
macular region was abnormally thin. However, retinal layers
at the macular area were still well conserved in this subject
(Figure 3(a)). Instead, the affected mother (subject II:1)
clearly presented disorganization of the retinal layers at
the macular region, and reduction in the retinal thickness
also appeared (Figure 3(b)). In the presence of common
genotype, electrophysiologic examination of the patients
detected intrafamilial variability of the phenotype involved
either the cones only or both cone and rod systems with
photopic amplitudes more markedly reduced than the
scotopic (Figure 4). The oldest subject (individual I:1) had
bilaterally undetectable cone response and subnormal rod
ERGs (Figure 4(b)), indicating a cone-rod phenotype with
severe loss of macular function (Figure 5(b)). Patients
II:1, III:1, and III:4 all presented from moderate (III:4) to
significantly reduced (II:1 and III:1) cone ERGs and normal
rod responses on full-field ERG (Figures 4(c), 4(e), and
4(f)), suggestive of cone dysfunction. Additional evidence
for macular dysfunction is presented as detected by mfERG
(Figure 5(d)) and OCT imaging (Figure 3). In patient II:3,
the full-field cone and rod ERGs were normal in both eyes
(Figure 4(d)), but the mfERG showed decreased central
amplitudes reflecting the macular dysfunction (Figure 5(c));
findings are consistent with isolated severe bilateral macular
degeneration and resulted in a loss of the central vision. No
abnormalities were observed in the EOGs in any patient
(Table 2). All affected individuals studied in detail were later
found to carry the p.L84F GUCA1Amutation.
3.2. Genotyping and Linkage Analysis. Five affected and
nine unaffected subjects of the Spanish family (Figure 1(a))
were genotyped with Affymetrix 250K SNP microarray, and
genome-wide linkage analysis was used to search for cosegre-
gation of the markers with the disease phenotype. Parametric
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Figure 2: Color fundus photographs of both eyes of patients carrying the mutation p.L84F in GUCA1A. (a), (b) Patient I:1 (75 y). Fundus
photographs showing an evident disc pallor and arteriolar attenuation, area of macular atrophy with pigment migration, choriocapillaris
atrophy surrounded this area, and the optic disc bilaterally. (c), (d) Patient II:1 (53 y). Fundus photographs showing bilateral temporal disc
pallor, mild arteriolar attenuation, and bull’s eye pattern of maculopathy. (e), (f) Patient II:3 (47 y). Funduscopy showing mild temporal disc
pallor, normal vessels, and perifoveal retinal pigment epithelium (RPE) alterations bilaterally. (g), (h) and (i), (j) Patients III:1 (25 y) and III:4
(12 y), respectively, presenting normal fundi.
multipoint analysis using Genehunter revealed a 55.37Mb
genomic interval between rs2894403 (35,507,179 bp) and
rs2474618 (90,876,844 bp) with a maximum likelihood odds
ratio score of 2.98 at a recombination fraction 0.0 suggestive
for linkage. Secondary peaks generating LOD score of 2.11
were observed for five different intervals on chromosomes
1, 7, 11, 12, and 16. Consequently, additional densely spaced
microsatellite markers spanning these regions were used
and haplotypes were constructed. Nonsegregation of STR-
haplotypes within the family allowed exclusion of all intervals
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Figure 3: Optical coherence tomography (OCT) macular cube 512× 128 scan showing macular thickness in individuals III:1 (a) and II:1
(b). For each scan, top left: fundus image with scan cube overlay. Top right: macular thickness significance map. The central innermost
1-mm-diameter circle represents the central subfield; inner superior, inner nasal, inner inferior, and inner temporal areas bounded by the
3-mm-diameter circle form the inner macula; outer superior, outer nasal, outer inferior, and outer temporal areas bounded by the 6-mm-
diameter circle form the outer macula. Retinal thickness values from ILM to RPE are compared to the normative data. Middle and bottom
left: cross-sectional OCT scans. Middle right: 3D surface maps: the ILM-RPE, displaying the retinal thickness in three dimensions, the ILM,
which appears normal in the two patients, and the RPE, which is altered in II:1. Bottom right: central subfield thickness, overall average
macular thickness, and overall macular volume compared to normative data are displayed in table format. Reduction in the retinal thickness
and macular atrophy of all retinal layers occurs in patient II:1. Abnormally thin macular region appears even in patient III:1 before obvious
ophthalmoscopic changes. ILM: inner limiting membrane; RPE: retinal pigment epithelium.
except the interval located on chromosome 6 which could
not be further refined. Affected individuals shared a common
haplotype tested with microsatellite markers spanning the
linked region and generating maximum LOD score of 2.10 at
𝜃 = 0.0 (Figure 1(a)).
3.3. Mutation Analysis. According to Ensembl human
genome database, the 55.37Mb critical interval on chromo-
some 6p21.31-q15 included 295 known genes among which
were previously described retinal degeneration genes.
Positional candidate genes were IMPG1 and ELOVL4,
mutations in which cause adMD [34, 35]; as well as RDS,
GUCA1A, and RIMS1, implicated in autosomal dominant
COD and CORD [9, 36, 37]. By direct sequencing of the
coding exons and intron-exon junctions of the candidate
genes, we found only known polymorphisms except a
novel heterozygous substitution c.250C>T in GUCA1A,
replacing leucine with phenylalanine at amino acid residue
84 (Figure 1(b)). Segregation analysis showed that the
novel mutation (p.L84F) co-segregated with the disease in
the pedigree (Figure 1(a)), but it was not detected in 200
unrelated normal controls. This variant was not reported in
public sequence repositories (including the 1000 Genomes
Project database, http://www.1000genomes.org/).
A restriction fragment length analysis confirmed the
c.250C>T mutation showing that the transition from C (wt)
to T (mutation) results in loss of SmlI restriction site. Wild-
type samples produced two fragments of 276 bp and 241 bp,
while the restriction target site (5󸀠-CTCAAG-3󸀠) in exon 4 of
GUCA1A was destroyed by the mutation (Figure 1(c)).
A second missense mutation c.320T>C (p.I107T), in
exon 4 of GUCA1A, was found in an index case (Family
387, individual III:2) after screening a cohort of 61 patients
(Figures 1(d) and 1(e)). No DNA was available from other
family members for testing of the cosegregation, but a family
history of adRD was reported (Family 387, Figure 1(d)).
Moreover, the variant was not found in 400 chromosomes
from ethnically matched control individuals and was novel
according to 1000Genomes Project data.The clinical findings
in this family were very similar to the complex phenotype of
Family 141 associated with the p.L84F GCAP1 mutation, and
major hallmarks are summarized in Table 2.
3.4. Mutation Prediction. Both missense mutations, p.L84F
and p.I107T (GenBank accession numbers JQ924784 and
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Figure 4: Right eye flash electroretinograms (ERGs) in patients I:1 (b), II:1 (c), II:3 (d), III:1 (e), and III:4 (f), carrying the mutation p.L84F,
in comparison with ERG of a representative control subject (a). Dark-adapted ERGs are shown for flash intensities of 0.01 and 3.0 cd⋅s/m2;
light-adapted ERGs and 30Hz flicker ERGs are shown for a flash intensity of 3.0 cd⋅s/m2.The electrophysiological findings are consistent with
cone-rod dystrophy with absent photopic response and decreased scotopic response in subject I:1 (b) or cone dystrophy showing photopic
ERGwith decreased photopic amplitudes in patients II:1, III:1, and III:4 ((c), (e), and (f)). Despite the progressive loss of visual acuity observed
in individual II:3, photopic ERG shows normal amplitudes (d). Implicit time of the scotopic response was normal whereas delayed photopic
responses were observed in all patients.
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Figure 5: Right eye multifocal ERG (mfERG) in individuals I:1 (b), II:3 (c), and III:4 (d) compared with mfERG of a representative control
subject (a). mfERG records reduced to nonrecordable central function.The ring analysis (see schematic) goes from the center to the periphery.
Quantitative results of mfERG analyses are displayed in table format.
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JQ924785, resp.), were located in amino acid residues well
conserved across different species (Figures 1(f) and 1(h)). By
PolyPhen-2 and PSIPRED programs, we further compared
the predicted consequences on protein secondary structure
of all reported GCAP1 mutations, p.P50L [3], p.E89K [4],
p.Y99C [6], p.D100E [4], p.N104K [7], p.T114I, p.I143NT [8],
p.L151F [9, 10], p.E155G [11], and p.G159V [4], as well as
of the two novel changes, p.L84F and p.I107T. PolyPhen-2
predicted a “probably damaging” effect for the two muta-
tions, with scores of 0.999 and 1.0, respectively (Table 1).
PSIPRED correctly predicted protein secondary structure
change in all 10 mutations known to cause reduction of
retinal guanylate cyclase-1 (RetGC1) activity [3–11] and also
for the new variant p.I107T (Table 1). Multiple changes of
the protein topology including shortening and/or increasing
of 𝛼-helices and coil stretches (caused by the mutations
p.P50L, p.E89K, p.Y99C, p.D100E, p.N104K, p.I107T, p.T114I,
p.I143NT, p.L151F, p.E155G, and p.G159V), as well as for-
mation of novel 𝛽-strands of 2-3 amino acids (caused by
the mutations p.P50L, p.E89K, p.Y99C, p.D100E, p.I143NT,
p.L151F, p.E155G, and p.G159V) were predicted. Interestingly,
PSIPRED predicted structural change for p.I107T at four
locations. 12 amino acid 𝛼-helix (residues 88–99, equivalent
to EF3) was shortened by two amino acids, 11 amino acid 𝛼-
helix (residues 132–142, equivalent to EF4) was increased by
one amino acid, 7 amino acid 𝛼-helix (residues 176–182) was
increased by one amino acid, and C-terminal 9 amino acid 𝛼-
helix (residues 191–199) was broken into two by one-residue
coil at position 193 (data not shown). No structural alterations
of the encoded protein were predicted for c.250C>T (p.L84F)
suggesting different mechanism of pathogenesis.
We hypothesized that the c.250C>T mutation could
function by disrupting a splicing enhancer and/or by the
creation of a splicing silencer because recognition of splice
sites can either be assisted by splicing enhancers or sup-
pressed by splicing silencers. Therefore, we scanned the
wild-type and c.250C>T mutant GUCA1A exon 4 sequence
for ESEs and ESSs using different web-based programs.
The results generated by ESEfinder 3.0 program indicated
that the 250T nucleotide abolishes SF2/ASF binding motif
(CTCAAGG) (Figure 1(g)). An overlapping SC35 binding
motif (GGTCCTCA) is also disrupted, while a second SC35
binding site (GTCCTCAA>GTCTTCAA) is not affected by
the mutation, but its score has been decreased from 3.572 to
3.341 (Table 4). Although Human Splicing Finder calculates
the score according to a different algorithm [26], the two
analyses gave similar results.
The ASD and ESRsearch programs identified that both
ESE (which promotes exon inclusion) and ESS (which
removes identified exon from the final product) elements
present on GUCA1A exon 4. These programs confirmed the
loss of SF2/ASF ESE site (CTCAAGG) caused by the mutant
allele. In addition, the c.250C>T mutation creates a new ESS
site for binding of SRp20 (GTCTTCAAG) and strengthens
the bindingmotif of the transacting splicing repressor hnRNP
I (CTTGGTCCTC>CTTGGTCTTC). ESRsearch program
predicted themutant TCTTCmotif as a gain of novel hnRNP
I binding ESS (Figure 1(g)).
4. Discussion
In this study, we identified a three-generation Spanish pedi-
gree representing intrafamilial heterogeneity of retinal degen-
eration with cone and rod involvement. The clinical obser-
vations revealed a range of retinal abnormalities, including
isolated macular dysfunction, cone dystrophy and cone-rod
dystrophy—findings very similar to previous descriptions of
the mixed phenotype associated with p.P50L and p.Y99C
GCAP1 mutation [5, 19]. The very early onset of visual loss
and the fast progression of the retinal dystrophy in the pre-
sented family contribute to the wide variability of phenotypes
associated with GCAP1 mutations. Combined with previous
studies, our findings support the hypothesis of additional
modifying factors (genetic and environmental) involvement,
which are responsible for themodulation of the phenotype in
patients harboring the same GUCA1Amutation [5].
Linkage to the GUCA1A locus was identified, and two
novel missense mutations, p.L84F and p.I107T, predicting
different mechanisms of pathogenesis were found in exon
4 of the GCAP1 coding gene (Figures 1(a)–1(e)). The Ile107
residue is located in a phylogenetically conserved motif
within the functional EF3 hand domain of the guanylate
cyclase-activating protein 1 (Figures 1(f) and 1(h)). The
result of PSIPRED analysis suggested that the novel p.I107T
mutation led to secondary structure changes affecting EF3,
EF4, and two C-terminal 𝛼-helices which may interfere
with the correct folding of the two helix-loop-helix Ca2+-
binding hands. A number of missense mutations associated
with either loss or gain of function and producing COD,
CORD, and MD dominant phenotypes have been already
discovered. By using PSIPRED, we predicted that each of
thesemutations (p.P50L, p.E89K, p.Y99C, p.D100E, p.N104K,
p.T114I, p.I143NT, p.L151F, p.E155G, and p.G159V) specifically
alter the conformation of the protein which is essential for the
Ca2+ binding (Table 1).
The p.I107T mutation represents the second naturally
occurring mutation in the 12-amino-acid-loop of the third
GCAP1 EF hand. Previously, a mutation (p.N104K) affecting
the Ca2+-binding loop of EF3 has been found to be causative
for adCOD [7]. It has been also reported that a mutation
of a residue flanking EF3 (p.Y99C) disrupts the N-terminal
helix of the helix-loop-helix conformation of EF3, severely
affecting Ca2+ binding at this site [6]. Another pathogenic
mutation of a flanking hydrophobic residue (p.I143NT) was
observed in EF4, emphasizing the importance of an intact N-
terminal helix for Ca2+ binding [8]. Other mutations linked
to cone dystrophy (p.E155G and p.L151F) affect exclusively
Ca2+ coordination in EF4 [9–11]. Commonbiochemical effect
of the mutations affecting one of the functional EF hands
consists of the inability of the mutant GCAPs to inhibit
photoreceptor GC in the dark when Ca2+ is elevated [38].
The result is that cGMP levels are elevated inmutant photore-
ceptors and a larger number of cation channels remain open,
which eventually leads to elevated Ca2+ concentration and to
photoreceptor cell death [39]. Taken together, all this data and
the fact that the mutation is of the missense type suggest sim-
ilar functional consequence of p.I107T, and the mechanism
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Table 4: ESEfinder 3.0 analyses of the wild-type and c.250C>T mutant exon 4 of GUCA1A.
Splicing factor mutation SF2/ASF threshold = 1.956 SC35 threshold = 2.383
Position (nt)a Motif Score Position (nt)a Motif Score
Wild type 49 CTCAAGG 2.216 45 GGTCCTCA 3.059
46 GTCCTCAA 3.572
GUCA1A-L84F 49 — — 45 — —
46 GTCTTCAA 3.341
aPosition of the first nucleotide of an ESE motif counted from the 5󸀠 boundary of exon 4 of GUCA1A.
of disease causation should be considered as either loss or
gain of function that affects calcium homeostasis within the
photoreceptor outer segment.
The mutation p.L84F is located in another phylogenet-
ically conserved motif flanking the functional EF2 hand
(Figures 1(f) and 1(h)). Although PolyPhen-2 predicted prob-
ably damaging effect for this mutation, no conformational
changes of the mutant protein were shown by PSIPRED
program (Table 1). Therefore, we used a set of computational
approaches to determine if this substitution alters specific cis-
acting elements that are important for correct splicing, such
as ESEs and ESSs, and acts at an earlier RNA level.
Two of the major factors in establishing exon identity
are serine- and arginine-rich proteins (SR proteins), among
which are SF2/ASF and SC35, and the heterogeneous nuclear
ribonucleoproteins (hnRNPs) [15]. SR proteins promote the
initial stages of spliceosome assembly by binding to ESEs and
recruiting basal splicing factors to adjacent splice sites or by
antagonizing the effects of ESS elements [40]. In contrast,
hnRNPs member among which is hnRNP I (also known
as polypyrimidine tract-binding protein, PTB), mediate the
repressive effects of silencers and can alter recruitment of the
core splicing machinery [41]. Surprisingly, since SR proteins
are typically thought to promote exon inclusion, it has
been demonstrated that interactions between SRp20, PTB,
and other hnRNPs create an exon silencing complex that
promotes exon skipping and cause inherited disease [42].
Our in silico analyses of exon 4-wild type and mutant
sequence indicated that naturally occurring SF2/ASF
(splicing factor 2/alternative splicing factor) ESE motif
(CTCAAGG) was abolished (SF2/ASF: 250C score = 2.216,
threshold = 1.956) suggesting that this heptamer might be
essential to distinguish a functional exon and its disruption
results in loss of activity. In addition, it was shown that the
c.250C>T mutation disrupted (SC35: 250C score = 3.059,
threshold = 2.383) a binding ESE motif (GGTCCTCA) and
weakened (SC35: 250C score = 3.572, 250T score = 3.341,
and threshold = 2.383) a second recognition site for the
RNA-binding protein SC35 (GTCCTCAA>GTCTTCAA)
(Table 4). A search for potential splicing silencer regulatory
elements within the GUCA1A exon 4 showed that the 250T
allele created a new ESS site (GTCTTCAAG) for binding
of SRp20 which is not present with 250C and strengthened
another binding motif (TCCT>TCTT) for hnRNP I/PTB
(Figure 1(g)), both designated as exon silencer partners
by Sterne-Weiler and coauthors [42]. It has been shown
that the loss of an ESE consensus motif for SF2/ASF can
cause human-inherited disease [43]. There are many other
examples for disease-associated mutations that alter splicing
enhancers or silencers and promote exon skipping, which
support our findings [42, 44–48]. Similarly, disease-causing
mutations in introns that cause missplicing by inducing
the inclusion of intronic sequences as exons (pseudoexon
inclusion) and function by strengthening of preexisting weak
pseudosplice sites or by creating new splice sites have been
discovered [49–51].
Based on this data, we concluded that the c.250C>T
mutation may function by disruption of SF2/ASF and SC35
binding ESEs and activation of cryptic ESS sites (for binding
of hnRNP I and SRp20) which promotes in-frame skipping
of exon 4 from the spliced mRNA. Thus, the expected
consequence of this mutation is production of aberrant
transcript that, if translated, would encode a truncated (50
amino acids shorter) protein copy suggesting either gain of
function or haploinsufficiency with cone cells predominantly
affected because of the higher concentrations of RetGC1 and
GCAP1 in cone photoreceptors.
5. Conclusions
In conclusion, we suggest that mutation associated with
disruption of ESE and activation of ESS cis-elements can
be applied to photoreceptor degeneration. Importantly, this
means that similar molecular mechanism may cause retinal
degeneration much more frequently than reported for aber-
rant spliced mRNA so far.
However, because of their predictive nature, these find-
ings need to be validated with experimental evidences in
order to see the real impact of the reported missense muta-
tions on the structure and conformation of GCAP1.
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